Photon Fusion Ltd is a biotech advisory practice. We read a platform company through three maps at once — the science, the patent landscape, and the competitive market — and then answer the question those maps exist to serve: what should you do next.
The three maps are not three separate reviews. They are three readings of the same platform, and the substantive work is where they disagree — where the construct design quietly narrows freedom to operate, where the differentiation claim outruns what the IP defends, where the milestone that looked like progress does not move the number an investor prices.
Most advice arrives siloed. Scientists advise on science, attorneys on patents, consultants on strategy. The disagreements between them are nobody's explicit responsibility — and that is exactly where they compound.
Where does the science hold at molecular resolution, and where does it rest on assumptions unlikely to survive scale-up, a cell-line swap, or a regulatory question? This reading operates at the bench, and it sets the boundaries within which the other two can see.
Patent landscape assessment, freedom-to-operate analysis, and strategic positioning — read for how IP decisions interact with technical choices and commercial claims, not in isolation from them.
A differentiation claim the science cannot carry, or the IP does not defend, will not survive diligence. This is where the technical and IP positions are stress-tested against the narrative the next round depends on.
Three ways this plays out day to day: technical choices at the bench — vector design, expression systems, synthesis workflows — quietly constrain what becomes patentable and what reaches market. A construct design narrows freedom to operate; a filing gap exposes a manufacturing route; these cross-domain dependencies are where risk accumulates before it locks in. And at inflection points — fundraising, licensing, pivots — the full picture matters: where the science stands, what the IP actually protects, and whether the commercial narrative survives diligence.
I am Dr Michal Legiewicz, I founded Photon Fusion Ltd because the most damaging failures in platform biotechnology are rarely failures of science, or of strategy, taken alone. They happen at the interfaces between technical design, IP architecture, and commercial positioning — interfaces that conventional advisory structures leave unowned. Scientific advisors assess the biology; patent attorneys assess claim scope; commercial consultants assess market strategy — and none of them is mandated to check whether those three assessments actually agree with each other. That gap is where platform value most often erodes.
My background sits across all three domains. Over two decades in nucleic acid science and technology took me from bench research at the NIH and Yale, through platform development at the University of Warwick and in UK biotech (Touchlight Genetics), to inventor-level patent work on DNA technologies. That combination of first-principles science, practitioner-level patent literacy, and commercial fluency is what catching interface failures actually requires, and it's an unusual one to find in a single advisor.
I work directly with founders, CSOs, and investors who want that kind of gap surfaced before it becomes a diligence finding — someone who can read the molecular biology at first principles, interpret a patent claim with practitioner-level judgment, and assess whether the resulting platform is a durable competitive asset or an inherited liability that simply hasn't come due yet.
My core expertise embraces nucleic acid biochemistry and biology, and its platform applications. This spans gene synthesis and vector design, gene editing and targeted delivery, DNA and mRNA therapeutics, and the emerging frontier where nucleic acid value is migrating next. Some of these areas I practise directly; others I monitor continuously because they shape the IP and commercial landscape in which my clients operate. The distinction matters, and the sections below make it explicit.
Gene design and synthesis, expression systems, construct engineering for manufacturability, and full-stack architecture of synthetic and enzymatic DNA platforms. The foundational layer on which all downstream applications depend, and where architectural decisions quietly determine what remains possible at manufacturing scale.
AAV vector design and non-viral targeted delivery platforms — the domain in which I have contributed directly as a researcher and named inventor. Platform decisions at this layer cascade into manufacturing, IP, and regulatory requirements, which is why the three-map reading is most consequential here.
Nucleic acid aptamer selection (SELEX), structural characterisation, and applications. A field where novel molecular structure intersects with IP opportunities and commercial territory that remain genuinely underexplored.
DNA and RNA nanotechnology, programmable nanostructures, and nucleic acid-based materials. Emerging platforms in which early IP and architectural decisions set long-term positioning.
DNA data storage, and molecular computing. Fields I track continuously because they indicate where nucleic acid IP and platform value are migrating next, even where they are not yet where I practise.
This is one vertex of three. It is the one that takes twenty years to acquire and cannot be read from a database.
It runs on two instruments, both built in-house, both documented. This is the one place on the site a two-card layout is correct — these are two co-equal instruments, not two businesses.
Where you actually stand. STMC integrates Cynefin, Wardley Mapping, and Intelligence Preparation of the Battlefield into a single reading of a platform's strategic terrain: what is knowable, what is evolving, and what a competitor is about to do about it.
Explore STMCWhich moves stay open, and which close if you wait. Path Painter traces the decision paths available from where you stand, and identifies the point at which each one forecloses.
Explore Path PainterToday these are practised as advisory. They are being built toward instruments a team can run without me.
Method is what we read. This is how we work. Engagements are structured to match the depth and continuity that each mandate requires. From embedded fractional leadership to discrete advisory sessions, the through-line is the same: substantive thinking that produces something worth having.
The deepest form of engagement. Photon Fusion Principal Advisor holds a defined fractional role — typically CTO or CSO — within the client's leadership structure, operating at approximately 20% of working time. This is not a consultancy arrangement wearing an operational title: it is a genuine strategic presence, with the access and continuity that genuine presence requires.
Platform understanding is built iteratively. By month three, the advisor knows the technology well enough to have opinions that matter — on IP architecture, platform positioning, investor narrative, and where the scientific programme and the commercial strategy are in tension.
A bounded engagement with a specific objective and a written deliverable. Typical projects include IP landscape review and whitespace mapping, platform technical assessment, competitive intelligence synthesis, or preparation for a fundraise or licensing discussion.
Scope is defined in a Statement of Work before commencement. Requests outside that scope are identified as such and quoted separately — not absorbed silently. The deliverable is written and stands on its own: not a presentation designed to generate the next meeting, but a document designed to be used.
One-off advisory sessions, expert calls, due diligence reviews, or advisory board participation. No fixed term, no operational involvement. Minimum booking of half a day ensures that any session produces something worth having rather than an introductory conversation dressed as advice.
This tier is also the natural entry point for a relationship that may evolve. Many Tier 1 and Tier 2 engagements begin with a Tier 3 conversation — a chance to assess fit before either party commits to something deeper.
Essays on where platform biotechnology actually fails, and the frameworks for navigating it.
Photon Fusion engages selectively, prioritising mandates where integrated scientific and strategic perspective can have the most decisive impact. If you are building a biotechnology platform and approaching decisions at which the scientific, IP, and commercial dimensions intersect, I would welcome hearing from you.